[HTML][HTML] Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki… - JCI insight, 2018 - ncbi.nlm.nih.gov
BACKGROUND. The PD-1–blocking antibody nivolumab persists in patients several weeks
after the last infusion. However, no study has systematically evaluated the maximum …
after the last infusion. However, no study has systematically evaluated the maximum …
[HTML][HTML] CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I …
T Otsuka, S Nishida, T Shibahara, B Temizoz… - BMC cancer, 2022 - Springer
Background Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN)(K3)—a novel
synthetic single-stranded DNA immune adjuvant for cancer immunotherapy—induces a …
synthetic single-stranded DNA immune adjuvant for cancer immunotherapy—induces a …
[HTML][HTML] Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: two case reports
T Koba, T Kijima, T Takimoto, H Hirata, Y Naito… - Medicine, 2017 - journals.lww.com
Rationale: Most of nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth
factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR …
factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR …
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin–Paclitaxel Treatment for Non …
M Tamiya, A Tamiya, T Yasue, K Nakao… - Anticancer …, 2016 - ar.iiarjournals.org
Aim: Malignant effusion is associated with high serum and plasma levels of vascular
endothelial growth factor (VEGF). There are no biomarkers of outcome for bevacizumab …
endothelial growth factor (VEGF). There are no biomarkers of outcome for bevacizumab …
Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias
T Arai, H Kida, Y Ogata, S Marumo, H Matsuoka… - …, 2019 - Wiley Online Library
Background and objective Acute exacerbation (AE) in idiopathic pulmonary fibrosis (IPF) or
other idiopathic interstitial pneumonias (IIP) is a poor prognostic event despite conventional …
other idiopathic interstitial pneumonias (IIP) is a poor prognostic event despite conventional …
[HTML][HTML] Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis
Y Naito, A Tamiya, M Tamiya, Y Kimura, M Hamaguchi… - Medicine, 2017 - journals.lww.com
Although small cell lung cancer (SCLC) is initially sensitive to chemotherapy, it recurs in
most cases. Standard regimens for salvage chemotherapy have not been established, and …
most cases. Standard regimens for salvage chemotherapy have not been established, and …
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of …
S Minami, T Kijima, M Hamaguchi, T Nakatani, T Koba… - Lung Cancer, 2013 - Elsevier
Introduction Erlotinib and pemetrexed have been approved for the second-line and
maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended …
maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended …
[HTML][HTML] A lung abscess caused by secondary syphilis–the utility of polymerase chain reaction techniques in transbronchial biopsy: a case report
S Futami, T Takimoto, F Nakagami, S Satoh… - BMC Infectious …, 2019 - Springer
Abstract Background In Japan and other countries, the number of patients with syphilis is
increasing year by year. Recently, the cases of the pulmonary involvement in patients with …
increasing year by year. Recently, the cases of the pulmonary involvement in patients with …
The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer
N Okamoto, H Suzuki, K Kawahara, K Honda… - Anticancer …, 2015 - ar.iiarjournals.org
Background: The alternatively spliced actinin-4 variant (ACTN4va) is expressed in small-cell
lung cancer (SCLC) and is thought to be a potential diagnostic marker. However, ACTN4va …
lung cancer (SCLC) and is thought to be a potential diagnostic marker. However, ACTN4va …
[HTML][HTML] Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding …
S Minami, T Kijima, R Takahashi, H Kida, T Nakatani… - BMC cancer, 2012 - Springer
Background Erlotinib and pemetrexed have been approved for the second-line treatment of
non-small cell lung cancer (NSCLC). These two agents have different mechanisms of action …
non-small cell lung cancer (NSCLC). These two agents have different mechanisms of action …